BioCorRx Reports 10,301.1% Revenue Growth to $797,244 in 2025

BioCorRx Inc. reported significant financial developments in its 10-K filing for the fiscal year ending December 31, 2025. The company achieved total net revenues of $797,244, a substantial increase from $7,665 in the previous year, marking a growth of 10,301.1%. This increase was primarily driven by the introduction of supply and distribution sales following the acquisition of assets related to Lucemyra, an FDA-approved medication for opioid withdrawal. Despite this revenue growth, BioCorRx recorded a net loss of $3,508,763, a decrease from the $5,212,102 loss reported in 2024, indicating improved financial performance.

The company’s operating expenses rose to $5,628,886 from $5,130,170 in the prior year, largely due to increased consulting and research and development costs. Notably, grant income also saw a significant rise, totaling $2,435,848 compared to $1,473,276 in 2024, attributed to funding from the National Institute on Drug Abuse (NIDA) for ongoing research into its lead product candidate, BICX104, a naltrexone implant for treating opioid use disorder. The company’s cash position improved slightly, ending the year with $139,360, up from $88,033 in 2024.

In terms of strategic developments, BioCorRx completed an asset purchase agreement with USWM, LLC, acquiring assets related to Lucemyra, which is expected to enhance its product offerings and revenue streams. The company also entered into several financing agreements, raising approximately $2.35 million through common stock subscription agreements, which will support its operational and developmental initiatives. As of March 1, 2024, BioCorRx was awarded an additional grant of $11,029,977 from NIDA to further its research on BICX104, which is anticipated to bolster its financial resources for the upcoming years.

Operationally, the company reported a decrease in the number of patients treated at licensed clinics, which impacted its revenue from membership and program fees. As of March 31, 2026, BioCorRx had approximately 12 licensed providers offering its recovery programs, indicating a need for increased market penetration and provider engagement to enhance product adoption rates. The company’s management has acknowledged the challenges in achieving market acceptance and is focused on expanding its network of licensed providers to improve patient access to its treatment programs.

Looking ahead, BioCorRx faces substantial challenges, including a working capital deficit of $7,491,731 and an accumulated deficit of $86,649,288, raising concerns about its ability to continue as a going concern. The company plans to address these issues through additional capital raises and strategic partnerships. However, there is no assurance that these efforts will be successful, and the company remains dependent on external financing to sustain its operations and execute its business plan.